These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31434650)

  • 1. Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.
    Jehl A; Cugnet-Anceau C; Vigouroux C; Legeay AL; Dalle S; Harou O; Marchand L; Lascols O; Caussy C; Thivolet C; Laville M; Disse E
    Diabetes Care; 2019 Oct; 42(10):2008-2010. PubMed ID: 31434650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired lipodystrophy associated with immune checkpoint inhibitors.
    Gnanendran SS; Miller JA; Archer CA; Jain SV; Hwang SJE; Peters G; Miller A
    Melanoma Res; 2020 Dec; 30(6):599-602. PubMed ID: 32141964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma.
    Falcao CK; Cabral MCS; Mota JM; Arbache ST; Costa-Riquetto AD; Muniz DQB; Cury-Martins J; Almeida MQ; Kaczemorska PC; Nery M; Teles MG
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3245-3248. PubMed ID: 30779841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
    Okamoto M; Okamoto M; Gotoh K; Masaki T; Ozeki Y; Ando H; Anai M; Sato A; Yoshida Y; Ueda S; Kakuma T; Shibata H
    J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
    BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity.
    Akturk HK; Alkanani A; Zhao Z; Yu L; Michels AW
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3589-3592. PubMed ID: 30124874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade.
    Eigentler T; Lomberg D; Machann J; Stefan N
    Ann Intern Med; 2020 Jun; 172(12):836-837. PubMed ID: 32120400
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.
    Martin-Liberal J; Furness AJ; Joshi K; Peggs KS; Quezada SA; Larkin J
    Cancer Immunol Immunother; 2015 Jun; 64(6):765-7. PubMed ID: 25828465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired generalized lipodystrophy under immune checkpoint inhibition.
    Haddad N; Vidal-Trecan T; Baroudjian B; Zagdanski AM; Arangalage D; Battistella M; Gautier JF; Lebbe C; Delyon J;
    Br J Dermatol; 2020 Feb; 182(2):477-480. PubMed ID: 31077337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
    Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
    Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
    Hofmann L; Forschner A; Loquai C; Goldinger SM; Zimmer L; Ugurel S; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Thomas I; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
    Eur J Cancer; 2016 Jun; 60():190-209. PubMed ID: 27085692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient.
    Sponghini A; Patrucco F; Giorgione R; Farinelli P; Zottarelli F; Rondonotti D; Savoia P
    Anticancer Drugs; 2017 Aug; 28(7):808-810. PubMed ID: 28489616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD-1 inhibitor therapy for metastatic melanoma.
    Singh P; Wolfe SP; Alloo A; Gottesman SP
    J Cutan Pathol; 2020 Jan; 47(1):65-69. PubMed ID: 31390071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.